You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Proteolytic Imaging of Remodeling Myocardium
SBC: Micro Vide, LLC Topic: NHLBIDESCRIPTIONprovided by applicantProteolytic Imaging of Remodeling Myocardium Abstract Heart attacksi emyocardial infarction or MIoccur in more thanmillion patients annuallyAdvances in interventional and pharmacological therapies have dramatically improved survival following the initial MIand patients are often surviving acute MI with more extensive myocardial injuryConsequentlythe number of patien ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Targeted Epigenetic Therapy for Triple-Negative Breast Cancer
SBC: PARKSIDE SCIENTIFIC INC. Topic: 102DESCRIPTIONprovided by applicantTriple negative breast cancerTNBCis one of the most aggressive forms of human cancerand currently has no targeted therapyChemotherapy is the only available treatment for TNBC patientsbut is deleterious and not effective once tumor spreadsTNBC represents a major unmet medical needaboutof breast cancer incidenceswomen worldwide inare TNBCTNBC disproportionally affects ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Screening the Ribosome for New Target Sites
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Streamlining HTS Assay Development through Direct Selection of Structure-Switching Aptamers
SBC: Bellbrook Labs, LLC Topic: 300Project Summary Abstract High throughput screening HTS is a powerful method for the discovery of new drug leads for target enzymes In HTS assays the activity of the target enzyme is often evaluated by quantifying a small molecule or cofactor that is produced or consumed by the enzyme While antibodies are a mainstay of small molecule detection as says they do have severe limitations which a ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Generation of antibodies to monitor Notch O-fucosylation in vivo
SBC: GLYCOSCIENTIFIC, L.L.C. Topic: 300Project Summary Notch is a cell surface protein that has diverse roles in human biology at all stages of life Notch is modified by a number of sugar structures including a number that are termed O fucose Alteration of the pattern of O fucose structures found on Notch has significant effects on Notch function which in turn has been linked to both developmental and adult pathologies includ ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel small-molecule targeted therapy for prostate cancer
SBC: MetCure Therapeutics LLC Topic: 102Enzalutamide resistance is a major obstacle in the treatment of metastatic castration resistant prostate cancer mCRPC Recently we developed a small molecule lead compound BKM and demonstrated its potent activity against bone metastatic prostate cancer cells In this Phase I STTR application we hypothesize that BKM is a novel targeted therapy to overcome enzalutamide resistance and eff ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Molecular Imaging of Early Stage of Liver Fibrosis by Novel Protein Agents
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: NIAAAAbstract Liver fibrosis cirrhosis is one of the most common outcomes of chronic liver disease Chronic liver disease is assessed by progressive fibrosis caused by repeated injury due to metabolic dysfunction alcohol abuse viral hepatitis or autoimmune disease If it is left unchecked liver fibrosis will progress to cirrhosis an advanced stage of the disease estimated to affect of the wor ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
DRUG DISCOVERY PLATFORM FOR PROTEIN ARGININE METHYLTRANSFERASE INHIBITORS
SBC: CH3 BIOSYSTEMS, LLC Topic: 300Project Summary Abstract The long term objective of this project is the generation of a universal drug discovery platform based on protein arginine methylation mechanisms involved in human disease The importance of protein arginine methylation in the context of human disease has become clear in the last few years with the realization that protein arginine methyltransferases and the target prot ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Expanding teleconsent capabilities to improve clinical research recruitment
SBC: Doxy.me Inc. Topic: NLMLack of recruitment of qualified research participants into clinical trials remains to be one of the most important issues in clinical research Studies often struggle to meet recruitment goals on time resulting in costly time extensions underpowered results and in some cases early termination Many reasons attribute to suboptimal recruitment including the challenges related to informing and c ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health